EpiCept regains compliance with Nasdaq minimum bid price requirement

EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced that Nasdaq notified the Company that it has regained compliance with the minimum bid price requirement in Listing Rule 5550(a)(2) and met the requirements of the Nasdaq Listing Qualification Panel (the “Panel”) decision dated November 2, 2009. Accordingly, the Panel has determined to continue the listing of the Company’s common stock on The Nasdaq Stock Market.

As previously announced, following a hearing before the Panel, the Panel determined to continue the Company’s listing subject to the condition that, on or before February 1, 2010, the Company evidence a closing bid price of $1.00 per share or more for at least the ten prior consecutive trading days. On January 29, 2010, the Company’s closing bid price was $2.29 per share, the tenth consecutive day it had exceeded the $1.00 per share threshold. Accordingly, the Company satisfied the Panel’s condition and the delisting proceeding is now closed.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.